Addex Therapeutics Key Executives
This section highlights Addex Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Addex Therapeutics
(Showing 0 of )
Addex Therapeutics Earnings
This section highlights Addex Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-04-25 | $-0.01 | $-0.86 |
| Read Transcript | Q3 | 2024 | 2024-11-22 | $-0.01 | $-2.77 |
| Read Transcript | Q2 | 2024 | 2024-09-30 | $-0.07 | $-1.77 |
| Read Transcript | Q1 | 2024 | 2024-06-06 | N/A | N/A |
| Read Transcript | Q4 | 2023 | 2024-04-18 | $-0.66 | $-4.06 |
| Read Transcript | Q3 | 2023 | 2023-11-29 | $-4.00 | $-4.07 |
| Read Transcript | Q2 | 2023 | 2023-08-10 | $-0.83 | $-5.00 |
| Read Transcript | Q1 | 2023 | 2023-05-12 | N/A | N/A |
Financial Statements
Access annual & quarterly financial statements for Addex Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $1.61M | $1.42M | $2.92M | $3.61M | $2.76M |
| Cost of Revenue | $6.94M | $14.62M | $12.82M | $10.37M | $230.10K |
| Gross Profit | $-5.32M | $-13.20M | $-9.90M | $-6.76M | $2.53M |
| Gross Profit Ratio | -329.99% | -928.06% | -339.55% | -187.12% | 91.67% |
| Research and Development Expenses | $6.96M | $14.67M | $12.84M | $10.37M | $12.45M |
| General and Administrative Expenses | $7.20M | $7.30M | $5.14M | $5.15M | $4.26M |
| Selling and Marketing Expenses | $-2.21M | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.99M | $7.30M | $5.14M | $5.15M | $4.26M |
| Other Expenses | $-6.96M | $-22.52K | $444.00K | $336.68K | $648.16K |
| Operating Expenses | $4.99M | $21.94M | $18.42M | $15.86M | $17.37M |
| Cost and Expenses | $11.89M | $21.94M | $18.42M | $15.86M | $17.37M |
| Interest Income | $63.96K | $29.25K | $5.32K | $35.30K | $36.87K |
| Interest Expense | $21.61K | $48.90K | $63.01K | $69.50K | $128.52K |
| Depreciation and Amortization | $305.95K | $323.14K | $347.61K | $378.75K | $333.84K |
| EBITDA | $-10.23M | $-20.23M | $-14.94M | $-12.41M | $-14.32M |
| EBITDA Ratio | -634.16% | -1422.11% | -512.34% | -343.51% | -518.25% |
| Operating Income | $-10.28M | $-20.52M | $-15.51M | $-12.24M | $-14.83M |
| Operating Income Ratio | -637.42% | -1442.61% | -531.70% | -338.88% | -536.92% |
| Total Other Income Expenses Net | $-274.93K | $-284.01K | $154.00K | $-615.33K | $-176.45K |
| Income Before Tax | $-10.56M | $-20.80M | $-15.35M | $-12.86M | $-14.78M |
| Income Before Tax Ratio | -654.47% | -1462.57% | -526.42% | -355.92% | -534.98% |
| Income Tax Expense | $- | $123.91K | $116.38K | $207.76K | $429.01K |
| Net Income | $-10.56M | $-20.80M | $-15.35M | $-12.86M | $-14.78M |
| Net Income Ratio | -654.47% | -1462.57% | -526.42% | -355.92% | -534.98% |
| EPS | $-16.80 | $-55.20 | $-54.00 | $-57.60 | $-67.20 |
| EPS Diluted | $-16.80 | $-55.20 | $-54.00 | $-57.60 | $-67.20 |
| Weighted Average Shares Outstanding | 619.23K | 376.54K | 284.33K | 222.35K | 220.24K |
| Weighted Average Shares Outstanding Diluted | 619.23K | 376.54K | 284.33K | 222.35K | 220.24K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $53.84K | $115.28K | $234.91K | $153.45K | $327.73K | $630.88K | $500.89K | $592.43K | $409.42K | $183.35K | $237.24K | $397.49K | $682.00K | $992.60K | $844.22K | $1.82M | $27.26K | $860.79K | $904.06K | $1.04M |
| Cost of Revenue | $- | $- | $-90 | $1.55M | $1.81M | $1.88M | $1.70M | $14.62M | $2.76M | $5.75M | $3.77M | $12.82M | $- | $3.73M | $2.75M | $2.52M | $1.98M | $2.32M | $57.74K | $3.62M |
| Gross Profit | $53.84K | $115.28K | $235.00K | $-1.39M | $-1.48M | $-1.24M | $-1.20M | $-14.03M | $-2.36M | $-5.56M | $-3.53M | $-12.42M | $682.00K | $-2.74M | $-1.90M | $-701.96K | $-1.95M | $-1.46M | $846.32K | $-2.58M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.04% | -907.72% | -452.30% | -197.22% | -240.19% | -2368.39% | -575.27% | -3034.39% | -1487.21% | -3124.89% | 100.00% | -275.97% | -225.51% | -38.55% | -7158.49% | -169.40% | 93.61% | -247.87% |
| Research and Development Expenses | $77.85K | $184.46K | $245.12K | $454.31K | $833.48K | $751.86K | $708.78K | $5.74M | $1.74M | $5.75M | $3.77M | $3.50M | $2.86M | $3.73M | $2.75M | $5.06M | $1.17M | $2.32M | $2.81M | $5.87M |
| General and Administrative Expenses | $337.25K | $507.17K | $571.74K | $1.70M | $1.75M | $1.95M | $1.80M | $-240.68K | $2.39M | $1.53M | $2.24M | $497.58K | $1.47M | $1.85M | $1.32M | $637.05K | $1.28M | $1.59M | $1.53M | $-799.34K |
| Selling and Marketing Expenses | $- | $- | $203.20K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $337.25K | $507.17K | $774.94K | $1.70M | $1.75M | $1.95M | $1.80M | $-240.68K | $2.39M | $1.53M | $2.24M | $497.58K | $1.47M | $1.85M | $1.32M | $637.05K | $1.28M | $1.59M | $1.53M | $-799.34K |
| Other Expenses | $260.94K | $322.97K | $- | $- | $- | $- | $390.13K | $-1.41M | $448.44K | $-3.09K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $676.04K | $1.01M | $1.02M | $2.84M | $2.98M | $3.18M | $2.90M | $4.09M | $4.58M | $7.28M | $6.00M | $4.67M | $4.26M | $5.50M | $3.99M | $3.70M | $3.14M | $3.83M | $5.18M | $4.40M |
| Cost and Expenses | $676.04K | $1.01M | $1.02M | $2.84M | $2.98M | $3.18M | $2.90M | $4.09M | $4.58M | $7.28M | $6.00M | $4.67M | $4.26M | $5.50M | $3.99M | $3.70M | $3.14M | $3.83M | $5.18M | $4.40M |
| Interest Income | $102 | $1.51K | $7.57K | $13.13K | $13.66K | $13.35K | $23.83K | $25.35K | $3.60K | $205 | $95 | $754 | $1.24K | $1.72K | $529.15K | $1.26K | $1.28K | $10.84K | $21.93K | $1.39K |
| Interest Expense | $586 | $864 | $611 | $8.36K | $3.50K | $3.83K | $5.92K | $7.77K | $6.38K | $129.24K | $61.24K | $9.34K | $9.99K | $22.94K | $20.74K | $10.27K | $12.53K | $18.14K | $28.56K | $- |
| Depreciation and Amortization | $53.58K | $112.38K | $2.94K | $79.39K | $75.38K | $75.41K | $75.78K | $75.65K | $77.32K | $83.35K | $86.83K | $82.97K | $87.74K | $88.26K | $88.64K | $87.08K | $99.01K | $96.51K | $96.16K | $96.66K |
| EBITDA | $-1.47M | $-1.34M | $-785.15K | $-2.77M | $-2.56M | $-2.60M | $-364.72K | $-3.57M | $-4.09M | $-7.13M | $-5.71M | $-4.33M | $-3.50M | $-4.58M | $-2.53M | $-2.03M | $-3.20M | $-3.00M | $-4.15M | $-3.35M |
| EBITDA Ratio | -2736.80% | -1165.47% | -334.23% | -1804.55% | -782.21% | -411.48% | -72.81% | -602.30% | -998.02% | -3886.24% | -2408.77% | -1089.76% | -513.26% | -461.31% | -299.71% | -111.36% | -11742.57% | -348.53% | -459.55% | -322.30% |
| Operating Income | $-622.20K | $-899.32K | $-788.09K | $-2.68M | $-2.65M | $-2.55M | $-2.40M | $-3.50M | $-4.17M | $-7.09M | $-5.76M | $-4.28M | $-3.58M | $-4.51M | $-3.15M | $-1.88M | $-3.11M | $-2.97M | $-4.27M | $-3.35M |
| Operating Income Ratio | -1155.71% | -780.13% | -335.49% | -1748.06% | -809.38% | -403.69% | -479.05% | -590.52% | -1017.78% | -3868.04% | -2429.04% | -1075.61% | -524.31% | -454.03% | -372.89% | -103.46% | -11418.10% | -345.48% | -472.61% | -322.53% |
| Total Other Income Expenses Net | $-905.37K | $-557.45K | $52.91K | $-174.43K | $35.54K | $-128.38K | $-2.35K | $-153.16K | $59.34K | $-129.04K | $-61.15K | $-148.54K | $-22.36K | $-183.51K | $508.42K | $-241.25K | $-200.00K | $-140.83K | $-33.24K | $-299.93K |
| Income Before Tax | $-1.53M | $-1.46M | $-735.18K | $-2.86M | $-2.62M | $-2.68M | $-2.41M | $-3.65M | $-4.11M | $-7.22M | $-5.82M | $-4.42M | $-3.60M | $-4.69M | $-2.64M | $-2.12M | $-3.31M | $-3.11M | $-4.31M | $-3.65M |
| Income Before Tax Ratio | -2837.40% | -1263.70% | -312.96% | -1861.73% | -798.54% | -424.04% | -480.58% | -616.38% | -1003.29% | -3938.42% | -2454.82% | -1112.98% | -527.59% | -472.51% | -312.67% | -116.71% | -12151.68% | -361.85% | -476.29% | -351.36% |
| Income Tax Expense | $- | $- | $3.09M | $8.36K | $3.50K | $3.83K | $58.02K | $46.12K | $53.84K | $205 | $95 | $9.34K | $9.99K | $22.94K | $529.15K | $10.27K | $12.53K | $18.14K | $28.56K | $-271.06K |
| Net Income | $-1.53M | $12.88M | $-3.09M | $-2.86M | $-2.62M | $-2.68M | $-2.41M | $-3.65M | $-4.11M | $-7.22M | $-5.82M | $-4.42M | $-3.60M | $-4.69M | $-2.64M | $-2.12M | $-3.31M | $-3.11M | $-4.31M | $-3.65M |
| Net Income Ratio | -2841.86% | 11171.90% | -1314.18% | -1861.73% | -798.54% | -424.04% | -480.58% | -616.38% | -1003.29% | -3938.42% | -2454.82% | -1112.98% | -527.59% | -472.51% | -312.67% | -116.71% | -12151.68% | -361.85% | -476.29% | -351.36% |
| EPS | $-1.88 | $15.60 | $-3.80 | $-3.60 | $-4.07 | $-4.45 | $-4.72 | $-7.34 | $-10.32 | $-22.80 | $-18.00 | $-15.60 | $-13.20 | $-16.80 | $-9.44 | $-9.53 | $-14.40 | $-14.40 | $-19.20 | $-16.80 |
| EPS Diluted | $-1.88 | $15.60 | $-3.80 | $-3.60 | $-4.07 | $-4.45 | $-4.72 | $-7.34 | $-10.32 | $-22.80 | $-18.00 | $-15.60 | $-13.20 | $-16.80 | $-9.44 | $-9.53 | $-14.40 | $-14.40 | $-19.20 | $-16.80 |
| Weighted Average Shares Outstanding | 812.79K | 812.79K | 812.79K | 793.64K | 643.99K | 601.57K | 510.41K | 497.46K | 398.21K | 312.23K | 315.79K | 289.81K | 284.35K | 283.83K | 279.33K | 223.05K | 222.39K | 222.24K | 221.71K | 219.44K |
| Weighted Average Shares Outstanding Diluted | 812.79K | 812.79K | 812.79K | 793.64K | 643.99K | 601.57K | 510.41K | 497.46K | 398.21K | 312.23K | 315.79K | 289.81K | 284.35K | 283.83K | 279.33K | 223.05K | 222.39K | 222.24K | 221.71K | 220.59K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.87M | $6.96M | $20.48M | $18.70M | $31.54M |
| Short Term Investments | $848 | $3.17K | $17.14K | $64.93K | $13.97K |
| Cash and Short Term Investments | $3.87M | $6.96M | $20.50M | $18.76M | $31.55M |
| Net Receivables | $151.27K | $598.32K | $324.42K | $68.37K | $118.03K |
| Inventory | $- | $-871.60M | $1 | $162.84K | $-13.97K |
| Other Current Assets | $217.01K | $270.39K | $1.12M | $661.22K | $720.06K |
| Total Current Assets | $4.23M | $7.83M | $21.94M | $19.49M | $32.39M |
| Property Plant Equipment Net | $352.94K | $398.73K | $542.10K | $633.10K | $570.97K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $54.34K | $54.35K | $57.91K | $59.14K | $68.91K |
| Total Non-Current Assets | $407.28K | $453.09K | $600.01K | $692.25K | $639.88K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $4.64M | $8.28M | $22.54M | $20.18M | $33.03M |
| Account Payables | $984.38K | $1.28M | $1.79M | $983.54K | $2.22M |
| Short Term Debt | $273.96K | $286.11K | $287.70K | $308.61K | $373.02K |
| Tax Payables | $164.61K | $120.88K | $203.29K | $171.88K | $107.42K |
| Deferred Revenue | $234.98K | $- | $- | $820.15K | $1.11M |
| Other Current Liabilities | $1.24M | $1.60M | $1.86M | $1.34M | $1.87M |
| Total Current Liabilities | $2.89M | $3.28M | $4.13M | $3.62M | $5.68M |
| Long Term Debt | $70.38K | $87.03K | $194.32K | $258.79K | $177.22K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $165.39K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $532.76K | $- | $1.28M | $1.69M | $1.65M |
| Total Non-Current Liabilities | $603.14K | $87.03K | $1.48M | $1.95M | $1.82M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $3.50M | $3.37M | $5.61M | $5.57M | $7.50M |
| Preferred Stock | $1 | $- | $- | $- | $- |
| Common Stock | $1.84M | $1.15M | $49.27M | $32.85M | $32.85M |
| Retained Earnings | $-360.42M | $-349.86M | $-329.06M | $-313.71M | $-300.85M |
| Accumulated Other Comprehensive Income Loss | $29.81M | $25.77M | $24.44M | $8.58M | $7.15M |
| Other Total Stockholders Equity | $329.91M | $327.85M | $272.28M | $280.81M | $286.38M |
| Total Stockholders Equity | $1.15M | $4.91M | $16.93M | $14.61M | $25.52M |
| Total Equity | $1.15M | $4.91M | $16.93M | $14.61M | $25.52M |
| Total Liabilities and Stockholders Equity | $4.64M | $8.28M | $22.54M | $20.18M | $33.03M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $4.64M | $8.28M | $22.54M | $20.18M | $33.03M |
| Total Investments | $848 | $3.17K | $17.14K | $64.93K | $13.97K |
| Total Debt | $344.34K | $373.13K | $482.01K | $567.40K | $550.25K |
| Net Debt | $-3.52M | $-6.58M | $-20.00M | $-18.13M | $-30.99M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $3.35M | $3.79M | $1.63M | $3.87M | $4.75M | $7.17M | $5.59M | $6.96M | $10.42M | $8.81M | $14.89M | $20.48M | $15.49M | $18.11M | $25.22M | $18.70M | $17.81M | $20.67M | $27.13M | $31.54M |
| Short Term Investments | $4.95K | $2.80K | $2.38K | $848 | $426 | $16.74K | $4.12K | $3.17K | $3.08K | $3.56K | $8.59K | $17.14K | $27.96K | $38.30K | $9.96K | $64.93K | $66.35K | $54.22K | $11.37K | $13.97K |
| Cash and Short Term Investments | $3.35M | $3.79M | $1.63M | $3.87M | $4.75M | $7.19M | $5.60M | $6.96M | $10.43M | $8.82M | $14.90M | $20.50M | $15.51M | $18.15M | $25.23M | $18.76M | $17.88M | $20.72M | $27.14M | $31.55M |
| Net Receivables | $516.51K | $616.43K | $225.05K | $151.27K | $373.37K | $502.28K | $431.47K | $598.32K | $457.04K | $410.02K | $434.63K | $324.42K | $582.47K | $1.23M | $183.72K | $68.37K | $75.84K | $104.00K | $67.45K | $118.03K |
| Inventory | $- | $- | $- | $- | $- | $1 | $- | $1 | $- | $1 | $- | $1 | $1 | $- | $- | $- | $- | $1 | $1 | $- |
| Other Current Assets | $201.34K | $283.19K | $1.44M | $217.01K | $614.81K | $1.00M | $884.28K | $270.39K | $817.66K | $1.72M | $1.83M | $1.12M | $1.34M | $1.63M | $852.56K | $661.22K | $1.29M | $1.86M | $1.12M | $720.06K |
| Total Current Assets | $4.07M | $4.69M | $3.29M | $4.23M | $5.74M | $8.69M | $6.91M | $7.83M | $11.70M | $10.95M | $17.16M | $21.94M | $17.44M | $21.00M | $26.27M | $19.49M | $19.25M | $22.69M | $28.32M | $32.39M |
| Property Plant Equipment Net | $44.83K | $29.38K | $32.32K | $352.94K | $341.05K | $252.51K | $325.42K | $398.73K | $481.38K | $377.84K | $461.18K | $542.10K | $566.01K | $472.20K | $548.80K | $633.10K | $329.74K | $386.72K | $482.94K | $570.97K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $21.68K | $72.90K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $21.68K | $72.90K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $8.02M | $8.90M | $- | $- | $54.35K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $7.06K | $7.07K | $7.07K | $54.34K | $- | $54.35K | $54.35K | $54.35K | $59.58K | $58.08K | $57.95K | $57.91K | $57.99K | $-472.20K | $59.47K | $59.14K | $68.17K | $68.58K | $68.86K | $68.91K |
| Total Non-Current Assets | $8.10M | $9.01M | $39.39K | $407.28K | $395.39K | $306.86K | $379.78K | $453.09K | $540.96K | $435.91K | $519.13K | $600.01K | $624.01K | $531.57K | $608.27K | $692.25K | $397.92K | $455.30K | $551.80K | $639.88K |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $12.17M | $13.70M | $3.33M | $4.64M | $6.14M | $9.00M | $7.29M | $8.28M | $12.24M | $11.38M | $17.68M | $22.54M | $18.06M | $21.53M | $26.87M | $20.18M | $19.65M | $23.15M | $28.88M | $33.03M |
| Account Payables | $325.78K | $302.38K | $1.63M | $984.38K | $389.78K | $1.11M | $1.08M | $1.28M | $2.99M | $1.82M | $1.42M | $1.79M | $1.16M | $1.21M | $2.23M | $983.54K | $433.25K | $958.45K | $2.24M | $2.22M |
| Short Term Debt | $7.21K | $12.39K | $12.24K | $273.96K | $206.41K | $199.88K | $222.79K | $286.11K | $285.92K | $242.78K | $292.10K | $287.70K | $290.99K | $258.67K | $302.69K | $308.61K | $215.25K | $289.89K | $355.00K | $373.02K |
| Tax Payables | $75.11K | $7.52K | $78.31K | $164.61K | $- | $- | $- | $120.88K | $133.11K | $- | $233.62K | $203.29K | $110.74K | $171.99K | $120.73K | $171.88K | $98.67K | $147.81K | $99.01K | $107.42K |
| Deferred Revenue | $- | $- | $- | $234.98K | $- | $- | $- | $- | $- | $- | $- | $- | $110.74K | $-258.67K | $13.36K | $820.15K | $149.94K | $219.97K | $708.11K | $1.11M |
| Other Current Liabilities | $479.46K | $620.70K | $2.94M | $1.24M | $1.33M | $1.40M | $1.89M | $1.60M | $714.74K | $2.23M | $2.03M | $1.86M | $1.71M | $2.04M | $1.95M | $1.34M | $1.32M | $1.19M | $2.26M | $1.87M |
| Total Current Liabilities | $887.56K | $942.99K | $4.65M | $2.89M | $1.93M | $2.71M | $3.19M | $3.28M | $4.13M | $4.30M | $3.97M | $4.13M | $3.27M | $3.68M | $4.61M | $3.62M | $2.22M | $2.81M | $5.67M | $5.68M |
| Long Term Debt | $36.55K | $19.79K | $22.95K | $70.38K | $116.90K | $32.63K | $36.33K | $87.03K | $161.18K | $94.17K | $120.77K | $194.32K | $230.23K | $161.49K | $187.11K | $258.79K | $53.69K | $74.59K | $103.65K | $177.22K |
| Deferred Revenue Non-Current | $- | $- | $- | $89.23K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $108.65K | $165.39K |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $181.91K | $83.11K | $31.53K | $532.76K | $145.77K | $125.86K | $- | $- | $- | $129.28K | $632.75K | $1.28M | $1.22M | $1.26M | $1.38M | $1.69M | $1.63M | $1.46M | $1.33M | $1.65M |
| Total Non-Current Liabilities | $218.47K | $102.90K | $54.48K | $603.14K | $262.67K | $158.50K | $36.33K | $87.03K | $161.18K | $223.44K | $753.52K | $1.48M | $1.45M | $1.42M | $1.56M | $1.95M | $1.69M | $1.54M | $1.43M | $1.82M |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $1.11M | $1.05M | $4.71M | $3.50M | $2.19M | $2.87M | $3.22M | $3.37M | $4.29M | $4.52M | $4.73M | $5.61M | $4.72M | $5.11M | $6.18M | $5.57M | $3.90M | $4.35M | $7.09M | $7.50M |
| Preferred Stock | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $988.98K | $- | $- | $- | $- | $- | $- |
| Common Stock | $1.84M | $1.84M | $1.84M | $1.84M | $1.42M | $1.36M | $1.15M | $1.15M | $652.73K | $65.27M | $65.27M | $49.27M | $49.27M | $49.27M | $39.75M | $32.85M | $32.85M | $32.85M | $32.85M | $32.85M |
| Retained Earnings | $-352.16M | $-350.63M | $-363.51M | $-360.42M | $-357.56M | $-354.94M | $-352.27M | $-349.86M | $-346.21M | $-342.10M | $-334.88M | $-329.06M | $-324.63M | $-321.04M | $-316.35M | $-313.71M | $-311.58M | $-308.27M | $-305.15M | $-300.85M |
| Accumulated Other Comprehensive Income Loss | $31.24M | $31.31M | $94.77M | $29.81M | $31.67M | $32.06M | $26.17M | $25.77M | $26.70M | $27.65M | $26.51M | $24.44M | $15.90M | $15.43M | $8.90M | $8.58M | $14.47M | $7.82M | $7.69M | $7.15M |
| Other Total Stockholders Equity | $330.13M | $330.13M | $330.14M | $329.91M | $328.41M | $327.64M | $329.02M | $327.85M | $326.81M | $256.05M | $256.06M | $272.28M | $272.80M | $272.75M | $288.39M | $280.81M | $280.01M | $286.40M | $286.39M | $286.38M |
| Total Stockholders Equity | $11.06M | $12.65M | $-1.38M | $1.15M | $3.94M | $6.13M | $4.07M | $4.91M | $7.95M | $6.86M | $12.96M | $16.93M | $13.34M | $16.42M | $20.70M | $14.61M | $15.74M | $18.80M | $21.78M | $25.52M |
| Total Equity | $11.06M | $12.65M | $-1.38M | $1.15M | $3.94M | $6.13M | $4.07M | $4.91M | $7.95M | $6.86M | $12.96M | $16.93M | $13.34M | $16.42M | $20.70M | $14.61M | $15.74M | $18.80M | $21.78M | $25.52M |
| Total Liabilities and Stockholders Equity | $12.17M | $13.70M | $3.33M | $4.64M | $6.14M | $9.00M | $7.29M | $8.28M | $12.24M | $11.38M | $17.68M | $22.54M | $18.06M | $21.53M | $26.87M | $20.18M | $19.65M | $23.15M | $28.88M | $33.03M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $12.17M | $13.70M | $3.33M | $4.64M | $6.14M | $9.00M | $7.29M | $8.28M | $12.24M | $11.38M | $17.68M | $22.54M | $18.06M | $21.53M | $26.87M | $20.18M | $19.65M | $23.15M | $28.88M | $33.03M |
| Total Investments | $8.03M | $8.90M | $2.38K | $848 | $426 | $16.74K | $4.12K | $3.17K | $3.08K | $3.56K | $8.59K | $17.14K | $27.96K | $38.30K | $9.96K | $64.93K | $66.35K | $54.22K | $11.37K | $13.97K |
| Total Debt | $43.77K | $32.18K | $35.19K | $344.34K | $323.32K | $232.52K | $259.12K | $373.13K | $447.11K | $336.95K | $412.87K | $482.01K | $521.22K | $420.16K | $489.80K | $567.40K | $268.93K | $364.48K | $458.65K | $550.25K |
| Net Debt | $-3.31M | $-3.76M | $-1.59M | $-3.52M | $-4.43M | $-6.94M | $-5.34M | $-6.58M | $-9.98M | $-8.48M | $-14.47M | $-20.00M | $-14.96M | $-17.69M | $-24.73M | $-18.13M | $-17.54M | $-20.31M | $-26.67M | $-30.99M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-10.56M | $-20.80M | $-15.35M | $-12.86M | $-14.78M |
| Depreciation and Amortization | $305.95K | $323.14K | $347.61K | $378.75K | $333.84K |
| Deferred Income Tax | $- | $- | $-150.59K | $-27.72K | $96.53K |
| Stock Based Compensation | $1.79M | $3.68M | $1.18M | $1.18M | $1.69M |
| Change in Working Capital | $213.76K | $157.68K | $-761.57K | $-1.82M | $2.66M |
| Accounts Receivables | $306.51K | $-252.09K | $-96.41K | $49.66K | $154.99K |
| Inventory | $- | $427.39K | $-883.84K | $1.54M | $-2.12M |
| Accounts Payables | $- | $-427.39K | $883.84K | $-1.59M | $1.97M |
| Other Working Capital | $-92.76K | $409.77K | $-665.15K | $-1.82M | $2.66M |
| Other Non Cash Items | $249.64K | $204.13K | $32.93K | $972.63K | $523.88K |
| Net Cash Provided by Operating Activities | $-7.99M | $-16.44M | $-14.71M | $-12.18M | $-9.48M |
| Investments in Property Plant and Equipment | $-6.84K | $-581 | $-31.55K | $-59.41K | $-28.46K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $-14.79K |
| Sales Maturities of Investments | $- | $3.55K | $1.24K | $- | $- |
| Other Investing Activities | $- | $3.55K | $1.24K | $- | $-14.79K |
| Net Cash Used for Investing Activities | $-6.84K | $2.97K | $-30.31K | $-59.41K | $-43.25K |
| Debt Repayment | $-281.79K | $-288.08K | $-309.62K | $-367.41K | $-316.79K |
| Common Stock Issued | $2.35M | $1.68M | $13.96M | $720.01K | $5.99K |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $3.20M | $1.71M | $2.75M | $-306.20K | $-152.89K |
| Net Cash Used Provided by Financing Activities | $5.26M | $3.10M | $16.40M | $46.40K | $-463.69K |
| Effect of Forex Changes on Cash | $-356.95K | $-196.22K | $122.47K | $-648.68K | $-144.30K |
| Net Change in Cash | $-3.09M | $-13.53M | $1.79M | $-12.84M | $-10.13M |
| Cash at End of Period | $3.87M | $6.96M | $20.48M | $18.70M | $31.54M |
| Cash at Beginning of Period | $6.96M | $20.48M | $18.70M | $31.54M | $41.67M |
| Operating Cash Flow | $-7.99M | $-16.44M | $-14.71M | $-12.18M | $-9.48M |
| Capital Expenditure | $-6.84K | $-581 | $-31.55K | $-59.41K | $-28.46K |
| Free Cash Flow | $-8.00M | $-16.44M | $-14.74M | $-12.24M | $-9.51M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.53M | $12.88M | $-735.18K | $-2.86M | $-2.62M | $-2.68M | $-2.41M | $-3.65M | $-4.11M | $-7.22M | $-5.82M | $-4.42M | $-3.60M | $-4.69M | $-2.64M | $-2.12M | $-3.31M | $-3.11M | $-4.31M | $-3.65M |
| Depreciation and Amortization | $53.58K | $112.38K | $2.94K | $79.39K | $75.38K | $75.41K | $75.78K | $75.65K | $77.32K | $83.35K | $86.83K | $82.97K | $87.74K | $88.26K | $88.64K | $87.08K | $99.01K | $96.51K | $96.16K | $96.66K |
| Deferred Income Tax | $- | $- | $- | $-389.21K | $-5.27K | $-9.15K | $- | $- | $- | $- | $- | $-11.54K | $38.85K | $12.02K | $-189.92K | $14.31K | $19.51K | $18.90K | $-80.44K | $20.70K |
| Stock Based Compensation | $- | $- | $386.03K | $389.21K | $483.46K | $490.60K | $431.20K | $684.77K | $898.00K | $659.26K | $1.44M | $274.33K | $381.06K | $336.85K | $186.10K | $230.18K | $305.44K | $343.08K | $297.71K | $317.93K |
| Change in Working Capital | $131.72K | $-2.36M | $562.85K | $1.58M | $-151.10K | $-778.09K | $-439.43K | $-385.20K | $551.78K | $586.24K | $-595.15K | $932.16K | $506.22K | $-2.48M | $280.54K | $2.17M | $24.42K | $-3.72M | $-289.60K | $2.83M |
| Accounts Receivables | $99.92K | $-471.40K | $-73.78K | $73.91K | $71.39K | $-25.24K | $186.46K | $-119.20K | $34.10K | $35.05K | $-202.04K | $34.25K | $-72.59K | $-53.28K | $-4.79K | $7.46K | $28.16K | $-36.55K | $50.58K | $209.30K |
| Inventory | $- | $- | $- | $-638.69K | $685.02K | $572.09K | $-5.21K | $791.11K | $303.71K | $-445.18K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $931.16K | $638.69K | $-685.02K | $-572.09K | $5.21K | $-791.11K | $-303.71K | $445.18K | $222.25K | $439.15K | $-435.66K | $-621.53K | $1.50M | $- | $- | $- | $- | $- |
| Other Working Capital | $31.80K | $-1.89M | $-294.53K | $1.51M | $-222.49K | $-752.85K | $-625.89K | $-266.00K | $517.68K | $551.18K | $-393.11K | $897.91K | $578.81K | $-2.43M | $285.33K | $2.17M | $24.42K | $-3.72M | $-289.60K | $2.83M |
| Other Non Cash Items | $946.10K | $-13.39M | $-2.88M | $572.05K | $-37.53K | $138.56K | $-19.82K | $204.57K | $-109.94K | $62.13K | $47.37K | $201.16K | $45.33K | $293.10K | $-494.64K | $330.61K | $306.78K | $213.47K | $121.78K | $416.66K |
| Net Cash Provided by Operating Activities | $-398.58K | $-2.76M | $-2.19M | $-623.02K | $-2.25M | $-2.76M | $-2.36M | $-3.07M | $-2.69M | $-5.83M | $-4.84M | $-2.94M | $-2.54M | $-6.45M | $-2.77M | $704.85K | $-2.56M | $-6.17M | $-4.16M | $22.88K |
| Investments in Property Plant and Equipment | $-1.27K | $- | $- | $-1.21K | $-678 | $-2.49K | $-2.47K | $-1 | $-580 | $- | $- | $-24.49K | $-1.67K | $-2.23K | $-3.16K | $-48.09K | $-695 | $-2.12K | $-8.51K | $-2.97K |
| Acquisitions Net | $-4.57K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-14.52K |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $-8 | $3.56K | $- | $- | $87 | $1.15K | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $4.67M | $- | $- | $- | $- | $- | $-8 | $3.56K | $- | $- | $87 | $1.15K | $- | $- | $- | $- | $- | $- | $-14.52K |
| Net Cash Used for Investing Activities | $-5.84K | $4.67M | $- | $-1.21K | $-678 | $-2.49K | $-2.47K | $-9 | $2.98K | $- | $- | $-24.40K | $-521 | $-2.23K | $-3.16K | $-48.09K | $-695 | $-2.12K | $-8.51K | $-17.49K |
| Debt Repayment | $-2.18K | $-3.00K | $-66.73K | $-69.05K | $-72.13K | $-26.60K | $-114.02K | $-66.97K | $-70.13K | $-75.92K | $-75.06K | $-73.90K | $-78.68K | $-79.44K | $-77.59K | $-86.10K | $-95.55K | $-94.17K | $-91.59K | $-90.22K |
| Common Stock Issued | $- | $- | $230.01K | $1.19M | $-126.99K | $- | $1.13M | $80 | $1.22M | $- | $- | $3.74M | $407 | $28.34K | $10.19M | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $-18.34K | $-15.23K | $- | $- | $- | $-5.03K | $-8.56K | $- | $- | $- | $- | $- | $12.12K | $-37.15K | $-2.60K | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.68K | $182.38K | $-5.50K | $-1.18M | $-116.83K | $4.53M | $-35.38K | $-102.01K | $3.03M | $-102.89K | $-660.73K | $4.49M | $-11.90K | $-404.86K | $-1.32M | $-171.86K | $-11.25K | $-7.29K | $-115.80K | $-1.39K |
| Net Cash Used Provided by Financing Activities | $-494 | $-57.41K | $163.28K | $-58.35K | $-188.96K | $4.48M | $1.03M | $-168.90K | $4.19M | $-170.25K | $-744.35K | $8.16M | $-90.18K | $-455.96K | $8.79M | $489.68K | $-94.68K | $-138.61K | $-209.99K | $-91.49K |
| Effect of Forex Changes on Cash | $-33.68K | $1.63K | $97.99K | $-206.04K | $26.80K | $-149.06K | $-28.65K | $-225.03K | $111.27K | $-74.44K | $-8.02K | $-188.83K | $7.59K | $-201.40K | $505.11K | $-264.85K | $-204.00K | $-148.02K | $-31.82K | $-326.09K |
| Net Change in Cash | $-438.60K | $2.16M | $-2.24M | $-888.63K | $-2.41M | $1.57M | $-1.36M | $-3.47M | $1.61M | $-6.07M | $-5.60M | $5.00M | $-2.62M | $-7.11M | $6.53M | $881.59K | $-2.86M | $-6.46M | $-4.41M | $-412.19K |
| Cash at End of Period | $3.35M | $3.79M | $1.63M | $3.87M | $4.75M | $7.17M | $5.59M | $6.96M | $10.42M | $8.81M | $14.89M | $20.48M | $15.49M | $18.11M | $25.22M | $18.70M | $17.81M | $20.67M | $27.13M | $31.54M |
| Cash at Beginning of Period | $3.79M | $1.63M | $3.87M | $4.75M | $7.17M | $5.59M | $6.96M | $10.42M | $8.81M | $14.89M | $20.48M | $15.49M | $18.11M | $25.22M | $18.70M | $17.81M | $20.67M | $27.13M | $31.54M | $31.95M |
| Operating Cash Flow | $-398.58K | $-2.76M | $-2.19M | $-623.02K | $-2.25M | $-2.76M | $-2.36M | $-3.07M | $-2.69M | $-5.83M | $-4.84M | $-2.94M | $-2.54M | $-6.45M | $-2.77M | $704.85K | $-2.56M | $-6.17M | $-4.16M | $22.88K |
| Capital Expenditure | $-1.27K | $- | $- | $-1.21K | $-678 | $-2.49K | $-2.47K | $-1 | $-580 | $- | $- | $-24.49K | $-1.67K | $-2.23K | $-3.16K | $-48.09K | $-695 | $-2.12K | $-8.51K | $-2.97K |
| Free Cash Flow | $-399.86K | $-2.76M | $-2.19M | $-624.23K | $-2.25M | $-2.76M | $-2.36M | $-3.07M | $-2.69M | $-5.83M | $-4.84M | $-2.97M | $-2.54M | $-6.45M | $-2.77M | $656.76K | $-2.56M | $-6.17M | $-4.17M | $19.91K |
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
$8.30
Stock Price
$6.80M
Market Cap
23
Employees
Geneva, None
Location
Revenue (FY 2023)
$1.61M
13.4% YoY
Net Income (FY 2023)
$-10.56M
49.3% YoY
EPS (FY 2023)
$-16.80
69.6% YoY
Free Cash Flow (FY 2023)
$-8.00M
51.3% YoY
Profitability
Gross Margin
-329.7%
Net Margin
-654.5%
ROE
-921.6%
ROA
-227.4%
Valuation
P/E Ratio
-0.32
P/S Ratio
2.12
EV/EBITDA
0.01
Market Cap
$6.80M
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-7.99M
51.4% YoY
Free Cash Flow
$-8.00M
51.3% YoY
Balance Sheet Summary
Total Assets
$4.64M
-44.0% YoY
Total Debt
$344.34K
7.7% YoY
Shareholder Equity
$1.15M
-85.8% YoY
Dividend Overview
No Dividend Data
Addex Therapeutics Ltd doesn't currently pay dividends.
Addex Therapeutics Dividends
Explore Addex Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Addex Therapeutics News
Read the latest news about Addex Therapeutics, including recent articles, headlines, and updates.
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 30, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it has entered into an option- and collaboration agreement with Sinntaxis AB (www.sinntaxis.com) for an exclusive license to intellectual property covering the use of metabotropic glutamate receptor subtype 5 (mGlu5) inhibitors for the treatment of brain injury recovery.
Addex Therapeutics Ltd (ADXN) Q4 2024 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2024 Earnings Conference Call April 25, 2025 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Peter Ehrlich - AikenSalt Raghuram Selvaraju - HC Wainwright & Co Tim Dyer Hello everyone. I would like to thank you all for attending our 2024 Full Year Financial Results Conference Call.
Addex Reports Full Year 2024 Financial Results and Provides Corporate Update
Launched Neurosterix with Perceptive Advisors, raising USD 65 million in Series A to advance preclinical portfolio Indivior selected GABAB PAM drug candidate and started IND enabling studies for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Repositioned our phase 2 mGlu5 NAM asset, dipraglurant in brain injury recovery Regained rights to our phase 2 mGlu2 PAM asset, ADX71149 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 25, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its full-year 2024 financial results for the period ended December 31, 2024 and provided a corporate update.
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 17, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that following the previously announced termination of development of ADX71149 (JNJ-40411813) in epilepsy, its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has return all development and commercialization rights to ADX71149 (JNJ-40411813) and the partnership between the two companies has been terminated.
Addex to Present at the 2025 Swiss Equities Baader Conference
Geneva, Switzerland, January 8, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that Dr Robert Lütjens, Head of Discovery - Biology, will present at the Swiss Equities Baader Conference being held in Bad Ragaz, Switzerland, January 08-10, 2025.
Addex Therapeutics Ltd (ADXN) Q3 2024 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q3 2024 Earnings Conference Call November 22, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Addex Therapeutics Third Quarter 2024 Financial Results and Corporate Update Conference Call.
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 22, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its third quarter financial results for the periods ended September 30, 2024, and provided a corporate update.
Addex Provisional 2024 Third Quarter Results Showed Net Loss Compared to Second Quarter 2024
Nine-month Results Remain On Track for Net Profit Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, November 11, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional third quarter net results decreased significantly compared to the second quarter 2024.
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q2 2024 Earnings Conference Call September 30, 2024 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and Chief Executive Officer Misha Kalinichev - Head, Translational Science Conference Call Participants Raghuram Selvaraju - H.C. Wainwright & Co. Operator Good day, and thank you for standing by.
Addex Therapeutics Reports 2024 Half Year and Second Quarter Financial Results and Provides Corporate Update
Launched Neurosterix with Perceptive Advisors to accelerate the development of M4PAM for schizophrenia Indivior selected GABA B PAM drug candidate for development in substance use disorders Addex selected independent GABAB PAM drug candidate for development in chronic cough Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 30, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its half-year and second quarter financial results for the periods ended June 30, 2024, and provided a corporate update.
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its provisional half-year and second quarter net results have increased significantly in 2024 compared to 2023 and first quarter 2024 results primarily due to the sale of part of its business to Neurosterix Pharma Sàrl on April 2, 2024.
Addex to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
Geneva, Switzerland, September 4, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that CEO, Tim Dyer, will be attending the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9 – 11, 2024, at the Lotte New York Palace Hotel.
Why Addex Therapeutics stock skyrocketed 70% on Tuesday
Addex Therapeutics Ltd (NASDAQ: ADXN) opened about 70% up this morning after making significant strides in its GABAB-positive allosteric modulator research. The clinical-stage pharmaceutical company has selected candidates for the PAM research that it's undertaking in collaboration with Indivior PLC, as per a press release on Tuesday.
Addex and Indivior Select Clinical Candidates from GABAB Positive Allosteric Modulator Research Collaboration
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, August 27, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, and Indivior PLC (NASDAQ/LSE: INDV) today announced the selection of clinical candidates from their GABAB positive allosteric modulator (PAM) research collaboration.
Addex's Partner Discontinues ADX71149 development in Epilepsy
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 22, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its partner Janssen Pharmaceuticals, Inc. (now known as J&J Innovative Medicine) has informed the company that it has discontinued development of ADX71149 (JNJ-40411813) in epilepsy.
Addex Presents Positive Results from GABAB PAM Cough Program at the Thirteenth London International Cough Symposium (13th LICS)
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 15, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that positive results from the Company's novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) chronic cough program will be presented during the Thirteenth London International Cough Symposium (13th LICS) on July 19 and an abstract is available to conference participants on-line from today.
Addex To Present at the Thirteenth London International Cough Symposium (13th LICS)
Geneva, Switzerland, July 12, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that Mikhail Kalinichev, Head of Translational Science, will present at the Thirteenth London International Cough Symposium taking place July 18 - 19, 2024 at Imperial College in London, U.K.
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 1, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2024 Annual General Meeting (AGM).
Addex Convenes Annual General Meeting 2024
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2024 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2024 Annual General Meeting will take place on Friday June 28, 2024, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am).
Addex Therapeutics to Release Q1 2024 Financial Results and Host Conference Call on June 6, 2024
Geneva, Switzerland, May 31, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that it will issue its Q1 2024 Financial Results on June 6, 2024. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and a review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) the same day.
Addex to Present at Bio€quity Europe 2024
Geneva, Switzerland, May 8, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Bio€quity Europe 2024 conference taking place May 12 - 14, 2024 at the Kursaal Congress Center in San Sebastián, Spain.
Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced top-line data from a Phase 2 epilepsy study evaluating adjunctive ADX71149 (JNJ-40411813) administration in patients with focal onset seizures with suboptimal response to levetiracetam or brivaracetam.
Addex to Present at the Swiss Biotech Day 2024
Geneva, Switzerland, April 19, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug development, announced today that CEO, Tim Dyer, will present at the Swiss Biotech Day 2024 conference taking place April 22 - 23, 2024 at the Congress Center in Basel, Switzerland.
Addex Therapeutics Ltd (ADXN) Q4 2023 Earnings Call Transcript
Addex Therapeutics Ltd (NASDAQ:ADXN ) Q4 2023 Earnings Conference Call April 18, 2024 10:00 AM ET Company Participants Tim Dyer - Chief Executive Officer Mikhail Kalinichev - Head, Translational Science Conference Call Participants Joanne Lee - Maxim Group Raghuram Selvaraju - H.C. Wainwright & Co. Michael Okunewitch - Maxim Group Operator Good day and thank you for standing by.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ADXN.